We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDRH: MORTALITY ASSESSMENTS KEY COMPONENT OF TRIAL DATA
CDRH: MORTALITY ASSESSMENTS KEY COMPONENT OF TRIAL DATA
April 2, 2004
Integrating mortality data into trial endpoints and throughout the total product life cycle is key for clinical trial sponsors, says Bram Zuckerman, director of the cardiovascular devices division at the FDA’s Center for Devices and Radiological Health.